Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.61 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.44 |
| ▸ | GNPAT | O15228 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
| ▸ | EPOR | P19235 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | CCKAR | P32238 | 2/20 | 0.37 |
| ▸ | CCKBR | P32239 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14114131 | 0.94 | GLP1R (0.70) | GLP1RFOLH1GNPATNOD1CCKAR | |
| SCHEMBL12806481 | 0.94 | GLP1R (0.70) | GLP1RFOLH1GNPATNOD1CCKAR | |
| SCHEMBL12806536 | 0.94 | GLP1R (0.70) | GLP1RFOLH1GNPATNOD1CCKAR | |
| SCHEMBL12296711 | 0.94 | GLP1R (0.70) | GLP1RFOLH1GNPATNOD1CCKAR | |
| SCHEMBL16948269 | 0.94 | GLP1R (0.70) | GLP1RFOLH1GNPATNOD1CCKAR | |
| SCHEMBL24486694 | 0.94 | GLP1R (0.70) | GLP1RFOLH1GNPATNOD1CCKAR | |
| SCHEMBL8248469 | 0.94 | GLP1R (0.70) | GLP1RFOLH1GNPATNOD1CCKAR | |
| SCHEMBL12296653 | 0.94 | GLP1R (0.70) | GLP1RFOLH1GNPATNOD1CCKAR | |
| SCHEMBL18573658 | 0.94 | GLP1R (0.70) | GLP1RFOLH1GNPATNOD1CCKAR | |
| SCHEMBL17401206 | 0.93 | GLP1R (0.69) | GLP1RFOLH1GNPATNOD1CCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150210747-A1 | PROTEASE STABILIZED ACYLATED INSULIN ANALOGUES | NOVO NORDISK AS (DK) | 2015-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210747-A1 | PROTEASE STABILIZED ACYLATED INSULIN ANALOGUES | IAPP, IDE, LIPE | GLP1R 54/4885FOLH1 524/4885GNPAT 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.